Matinas BioPharma Holdings, Inc. Annual Report - How They Did This Year

I am writing this guide to help you understand how Matinas BioPharma performed this year. My goal is to turn complex filing information into simple terms to help you decide if this company fits your investment goals.

1. What does this company do and how did they perform this year?

Matinas BioPharma is a clinical-stage drug company focused on a "lipid nanocrystal" (LNC) platform. This technology aims to deliver drugs orally that are usually hard to absorb or require toxic IV injections. Because they are still testing their drugs, they earned $0 in product sales for the year ending December 31, 2024. Their main asset, MAT2203, is designed to treat fungal infections. Without products to sell, the company relies entirely on outside cash to cover its $15 million to $20 million annual operating costs.

2. A Year of Major Setbacks

The past year was defined by the collapse of the company’s main business strategy. In October 2024, Matinas ended licensing talks for MAT2203. This deal was intended to provide the cash needed to start the Phase 3 ORALTO trial without issuing more shares.

After this deal failed, the company launched a severe plan to save cash. They cut their workforce by 80% and stopped all internal research, including work on the LNC platform. The company now operates with a skeleton crew and is focused entirely on finding a buyer, a merger partner, or someone to license their intellectual property.

3. Financial Health and "Survival" Moves

Matinas is currently facing extreme cash shortages. Their current cash will not cover operations past the second quarter of 2025 without raising more money.

• The Stock Split: On August 23, 2024, the company performed a 1-for-50 reverse stock split to keep their share price above the $1.00 minimum required by the NYSE American exchange.
• Recent Cash Infusions: In January 2025, the company raised $3.3 million by selling preferred stock and warrants. This move is highly dilutive; when these shares are converted, the company will issue more shares, which reduces your ownership percentage and potential earnings per share.

4. Key Risks

The risks for Matinas are extreme and threaten the company’s survival.

• No Revenue and High Costs: With no products to sell, the company has no income. They rely on selling more shares to stay alive, which lowers the value of your current investment.
• The "Go-Forward" Uncertainty: The ORALTO trial is paused, meaning their lead asset is stalled. Phase 3 trials can cost $50 million to $100 million. Without a partner to pay these costs, the path to FDA approval is blocked.
• Delisting and Liquidity: Even after the reverse split, the share price could drop again, risking a delisting. Also, low trading volume makes the stock very volatile, meaning small sell orders can cause the price to drop sharply.

5. The Bottom Line

Matinas is a high-stakes situation. The company has shifted from a research-focused biotech to a distressed entity looking for a buyer. This is not a traditional growth investment; it is a binary bet on whether management can find a buyer or partner before they run out of cash. If they fail, the company may go bankrupt, which would likely result in a total loss for shareholders.

Decision Tip: Before investing, ask yourself if you are comfortable with the high probability of dilution or total loss in exchange for the slim chance of a successful buyout. If you prefer stability or long-term growth, this company’s current financial state may not align with your strategy.